Quantitative analysis of AAV capsid heterogeneity with mass photometry

Cell & Gene Therapy Insights 2025; 11(5), 715

DOI: 10.18609/cgti.2025.079

Published: 14 July
FastFacts
Maria Jacintha Victoria


Ensuring the efficacy and regulatory compliance of AAV-based gene therapies depends on critical quality attributes such as purity, potency, and safety. However, AAV preparations are often heterogeneous, containing capsid-related impurities that can reduce therapeutic effectiveness and increase production costs. This poster highlights how to achieve fast and accurate mass photometer analysis for characterizing AAV populations.


NEW INTERACTIVE FORMAT

Listen to our expert speaker. Watch the video. Read the summary. Focus in on the data. Download the PDF. It has never been easier to quickly access the information you want. All in one place—at the click of a button.